Cargando…

Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice

Background: Nonalcoholic steatohepatitis (NASH) is the most severe form of non-alcoholic fatty liver disease (NAFLD) and a potential precursor of hepatocellular carcinoma (HCC). In our previous studies, we found that endocrine fibroblast growth factor 21 (FGF21) played a key role in preventing the d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Youxi, Shi, Xiaoju, Zheng, Qianqian, Wang, Xingtong, Liu, Xingkai, Tan, Min, Lv, Guoyue, Zhang, Ping, Martin, Robert C., Li, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315028/ https://www.ncbi.nlm.nih.gov/pubmed/34326695 http://dx.doi.org/10.7150/ijbs.58776

Ejemplares similares

Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling
por: Zheng, Qianqian, et al.
Publicado: (2020)

FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis
por: Liu, Cong, et al.
Publicado: (2023)

Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB
por: Yang, Chaofeng, et al.
Publicado: (2012)

Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity
por: Agrawal, Archita, et al.
Publicado: (2018)

Schisandra lignans ameliorate nonalcoholic steatohepatitis by regulating aberrant metabolism of phosphatidylethanolamines
por: Xue, Lijuan, et al.
Publicado: (2023)

FGF/FGFR signaling in health and disease
por: Xie, Yangli, et al.
Publicado: (2020)

Multi-organ FGF21-FGFR1 signaling in metabolic health and disease
por: Kaur, Namrita, et al.
Publicado: (2022)

Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis
por: Matye, David J., et al.
Publicado: (2021)

Second malignant neoplasms in lymphomas, secondary lymphomas and lymphomas in metabolic disorders/diseases
por: Yu, Youxi, et al.
Publicado: (2022)

Necroptosis in Nonalcoholic Steatohepatitis
por: Gautheron, Jérémie, et al.
Publicado: (2015)

miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice
por: Rodrigues, Pedro M, et al.
Publicado: (2017)

miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice
por: Rodrigues, Pedro M, et al.
Publicado: (2017)

FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
por: Tillman, Erik J., et al.
Publicado: (2020)

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
por: Ruan, Ruiwen, et al.
Publicado: (2023)

Expression of FGF8, FGF18, and FGFR4 in Gastroesophageal Adenocarcinomas
por: Jomrich, Gerd, et al.
Publicado: (2019)

FGF21-FGFR1 controls mitochondrial homeostasis in cardiomyocytes by modulating the degradation of OPA1
por: Yan, Bing, et al.
Publicado: (2023)

Emerging Roles of Liver Sinusoidal Endothelial Cells in Nonalcoholic Steatohepatitis
por: Furuta, Kunimaro, et al.
Publicado: (2020)

Apoptosis and diagnosis of nonalcoholic steatohepatitis
por: Kim, Chang Wook, et al.
Publicado: (2011)

Antioxidant Therapy in Nonalcoholic Steatohepatitis
por: Al-Busafi, Said A., et al.
Publicado: (2012)

The Immune Landscape in Nonalcoholic Steatohepatitis
por: Narayanan, Sowmya, et al.
Publicado: (2016)

Betel Chewing and Nonalcoholic Steatohepatitis
por: Bleibel, Wissam, et al.
Publicado: (2018)

The metabolic basis of nonalcoholic steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
por: Parthasarathy, Gopanandan, et al.
Publicado: (2020)

Insulinoma in Patient With Nonalcoholic Steatohepatitis
por: Cain, Daniel, et al.
Publicado: (2023)

Challenges and opportunities in nonalcoholic steatohepatitis
por: Wang, Xiaobo
Publicado: (2022)

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
por: Meric-Bernstam, Funda, et al.
Publicado: (2022)

TNF-Like Ligand 1 Aberrance Aggravates Nonalcoholic Steatohepatitis via M1 Macrophage Polarization
por: Luo, Yuxin, et al.
Publicado: (2021)

miR-22 inhibition reduces hepatic steatosis via FGF21 and FGFR1 induction
por: Hu, Ying, et al.
Publicado: (2020)

Comprehensive Landscape of Cyclin Pathway Gene Alterations and Co-occurrence with FGF/FGFR Aberrations Across Urinary Tract Tumors
por: Jardim, Denis L F, et al.
Publicado: (2022)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Wilson's disease masquerading as nonalcoholic steatohepatitis
por: Mahmood, Sabina, et al.
Publicado: (2009)

Familial Hypobetalipoproteinemia-Induced Nonalcoholic Steatohepatitis
por: Lam, Mindy C.W., et al.
Publicado: (2012)

The effect of β-caryophyllene on nonalcoholic steatohepatitis
por: Arizuka, Naoya, et al.
Publicado: (2017)

New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis
por: Mendez-Sanchez, Nahum, et al.
Publicado: (2018)

Repurposing drugs to target nonalcoholic steatohepatitis
por: Sookoian, Silvia, et al.
Publicado: (2019)

The regulatory state of nonalcoholic steatohepatitis and metabolism
por: Omokaro, Stephanie O., et al.
Publicado: (2020)

Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
por: Sumida, Yoshio, et al.
Publicado: (2020)

Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis
por: Hwang, Seonghwan, et al.
Publicado: (2021)

The Role of the Intestinal Microbiota in Nonalcoholic Steatohepatitis
por: Xiang, Hui, et al.
Publicado: (2022)

Human Nonalcoholic Steatohepatitis on a Chip
por: Freag, May S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qfgk115erdg55k2sf2culukkjm